RaQualia Pharma Inc. announced consolidated financial results for the six months ended June 30, 2020. For the six months, the company expects the net sales of JPY 372 million as compared to JPY 545 million a year ago. Operating loss was JPY 403 million as compared to JPY 302 million a year ago. Loss was JPY 459 million as compared to JPY 310 million a year ago. Basic loss per share was JPY 21.93 as compared to JPY 15.19 a year ago.